Brian Calimlim
0000-0002-6463-6433
AbbVie Inc.
2 papers found
Refreshing results…
Aggregate Response Benefit in Skin Clearance and Itch Reduction With Upadacitinib or Dupilumab in Patients With Moderate-to-Severe Atopic Dermatitis®
Upadacitinib Rapidly Improves Patient-Reported Outcomes in Atopic Dermatitis: 16-Week Results from Phase 3 Clinical Trials (Measure Up 1 and 2)
Missing publications? Search for publications with a matching author name.